Blinatumomab for treatment of refractory myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial is testing a new medication called blinatumomab for people with difficult-to-treat myasthenia gravis, a condition that causes muscle weakness. The drug aims to help reduce symptoms and improve quality of life for those who haven't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have a confirmed diagnosis of myasthenia gravis, based on typical symptoms and positive tests.
- Your condition is considered 'refractory', meaning standard treatments have not worked well enough or you have had a serious crisis.
- You are on a stable dose of your current medications.
- You do not have a thymoma, have not had thymectomy in the last 6 months, and do not have certain severe health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new treatment for people with generalized myasthenia gravis (a condition causing muscle weakness) that hasn't improved with standard medications. The treatment, called blinatumomab, aims to reduce weakness by targeting certain immune cells.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.